Investor clashes with Akorn board after botched Fresenius tie-up

An investor has urged an Illinois federal court to disregard Akorn’s motion to dismiss their lawsuit, after a merger between the drugmaker and healthcare company Fresenius collapsed following revelations that the drugmaker misrepresented the state of its data.

Unlock unlimited access to all Global Data Review content